SNDX Q2 2019 Earnings — Syndax Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

SNDXSyndax Pharmaceuticals, Inc.

$2B

Q2 2019 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$379,000+0.0% YoY

Gross Profit

$379,000100.0% margin

Operating Income

-$15M-4056.5% margin

Net Income

-$15M-3935.6% margin

EPS (Diluted)

$-0.47

QoQ Revenue Growth

+0.0%

Cash Flow

Operating Cash Flow

-$13M

Free Cash Flow

-$13M

Stock-Based Comp.

$1M

Balance Sheet

Total Assets

$87M

Total Liabilities

$32M

Stockholders' Equity

$55M

Cash & Equivalents

$27M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$379,000	$379,000	+0.0%
Gross Profit	$379,000	$379,000	+0.0%
Operating Income	-$15M	-$19M	+18.9%
Net Income	-$15M	-$18M	+18.9%